HRTX Stock Summary and Trading Ideas (Heron Therapeutics | NASDAQ:HRTX)

Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Heron Therapeutics trades on the NASDAQ stock market under the symbol HRTX.

As of March 20, 2026, HRTX stock price declined to $0.78 with 1,935,467 million shares trading.

HRTX has a beta of 1.03, meaning it tends to be more sensitive to market movements. HRTX has a correlation of 0.09 to the broad based SPY ETF.

HRTX has a market cap of $142.73 million. This is considered a Micro Cap stock.

Last quarter Heron Therapeutics reported $41 million in Revenue and -$.02 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.01.

In the last 3 years, HRTX traded as high as $3.93 and as low as $.50.

The top ETF exchange traded funds that HRTX belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

HRTX has underperformed the market in the last year with a price return of -68.2% while the SPY ETF gained +15.6%. HRTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -40.1% and -23.7%, respectively, while the SPY returned -4.7% and -4.8%, respectively.

HRTX support price is $.77 and resistance is $.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HRTX shares will trade within this expected range on the day.